Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Highlights Innovations in Scalable, High-Throughput Transient Transfection for Cell Based Assays at the SLAS2013 Conference and Exhibition in Orlando, Booth #428
January 11, 2013
MaxCyte Presents Worldwide Customer Data Demonstrating Unmatched Cell Compatibility and Applicationsin Cell Based Assay
Gaithersburg, Maryland - MaxCyte, Inc.,the pioneer in scalable, high performance cell loading systems, is hosting a series of events at the 2 nd Annual Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition to be held January 13-16, in Orlando, FL. MaxCyte will conduct a tutorial, present a scientific poster, and schedule one-on-one discussions in Booth #428 to demonstrate how the MaxCyte Scalable Transfection Systems can improve the physiological relevance and quality of cellular screening campaigns.
At the conference, MaxCyte will conduct a tutorial entitled "Streamlined Receptor Screening: Ion Channels, GPCRs and Transporter Screening in Biologically Relevant Cells Using Large-Scale Transient Transfection" on Tuesday, January 15, 2013, at 12:30 PM in rooms Gainesville 1-2 at the Gaylord Palms Resort & Convention Center. In this tutorial, Dr. James Brady, Director of Technical Applications at MaxCyte, will present specific case studies from around the world demonstrating the broad cell type compatibility ofthe MaxCyte STX, including stem cells, primary cells, insect cells, and other difficult-to-transfect cell lines, along with the performance of these transfected cells in downstream applications for cell-based screening and protein production. Highlighted in Dr. Bradys presentation will be the complementary performance of the MaxCyte flow electroporation technology with downstream assay platforms.
MaxCyte will also present a scientific poster entitled "Development of Fully Scalable ReporterGene Assaysfor Studying Transcriptional Regulation & Receptor Activation Using Flow Electroporation" (poster # MP 163). MaxCyte scientists will be available at this poster on Monday, January 14, from 1:00 to 3:00 PM for further discussion of these data.